Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Calls Roche’s Arthritis Drug Actemra Effective Ahead Of Panel Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

First-in-class interleukin-6 receptor inhibitor may sidestep safety concerns seen with anti-TNFs.

You may also be interested in...

NICE Affirms Guidance Denying Coverage Of Sequential TNF Inhibitors In RA

Makers of Humira, Enbrel and Remicade had appealed a negative 2006 appraisal, prompting a second look by UK health care agency.

Roche’s Actemra Beats Methotrexate In Rheumatoid Arthritis

Interleukin-6 inhibitor is first biologic to show superiority in reducing signs and symptoms.

Roche’s Actemra Gets Advisory Committee Review

FDA’s Arthritis Drugs Advisory Committee evaluates the interleukin-6 receptor inhibitor for rheumatoid arthritis July 29.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts